Environmental toxicants and cardiovascular health trajectories across childhood and adolescence
Active Project Grant Awarded Last action
- Award ID
- R01HL183379
- Recipient
-
Harvard Pilgrim Health Care, Inc. UEI NZVVQ8GNVX65
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $571,839
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 7% complete
- Place of performance
- Boston, MA 02215, USA
Award details come from USAspending.gov.
About this award
The National Heart, Lung, and Blood Institute awarded Harvard Pilgrim Health Care, Inc. Office of Sponsored Programs $571,839 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL183379) to investigate how early-life exposure to environmental toxicants influences cardiovascular health trajectories in children and adolescents.
The research leverages data from 1,332 mother-child pairs enrolled in Project Viva, a prospective pre-birth cohort in eastern Massachusetts with over two decades of follow-up. The study examines associations between prenatal and postnatal exposures to toxic metals (cadmium, lead), per- and polyfluoroalkyl substances, and air pollution on cardiovascular health trajectories from childhood through adolescence, assessed using the American Heart Association's Life's Essential 8 framework. The work includes evaluation of effect modification by maternal and child lifestyle factors and identification of metabolomic signatures underlying cardiovascular health decline.
Performance occurs in Boston, Massachusetts through June 30, 2030. The award addresses primordial prevention—a core NHLBI priority—by examining precursors of adult cardiovascular disease that emerge as early as age three years, including elevated body mass index, high blood pressure, and dyslipidemia.
Description
- Abstract
- Cardiovascular disease (CVD) is the leading cause of death in the united states. Its precursors, including high body mass index, elevated blood pressure, and dyslipidemia, emerge as early as age 3 years and strongly pre- dict adult CVD events and mortality. These findings underscore the urgent need for primordial prevention, a core priority of nhlbi, which focuses on promoting and preserving cardiovascular health (CVH) before disease onset. The american heart association's life's essential 8 construct provides a validated framework for as- sessing CVH across the lifespan using eight behavioral and biological parameters. This construct is also a strong indicator of future CVD events, whereby higher (BETTER) CVH scores confers lower risk of adult CVD. Emerging evidence, including findings from our preliminary work, suggests that early-life exposure to environ- mental toxicants such as toxic metals (e.g., cadmium, lead), per- and polyfluoroalkyl substances, and air pollu- tion, may accelerate CVH decline through shared metabolic pathways including oxidative stress, endothelial dysfunction, and lipid dysregulation. However, the extent to which these toxicants influence CVH trajectories in children remains poorly understood. This R01 proposal will leverage data from 1,332 mother-child pairs in pro- ject viva, a well-characterized NIH-funded prospective pre-birth cohort in eastern massachusetts with over two decades of follow-up. The study will: 1) investigate associations between prenatal toxicant exposures and CVH trajectories from childhood to adolescence, and assess effect modification by maternal lifestyle factors (aim 1); 2) examine associations between postnatal toxicant exposures and CVH trajectories, and evaluate effect modi- fication by both maternal and child lifestyle factors (aim 2); and 3) identify metabolomic signatures underlying CVH decline and assess their potential as biomarkers of toxicant exposure (aim 3). Innovative features of this proposal include assessment of toxicant mixtures during sensitive developmental windows (i.e., pregnancy and childhood), advanced modeling of CVH trajectories from childhood to adolescence using modern analytical methods, and integration of untargeted metabolomics to uncover novel pathophysiologic mechanisms. Find- ings from this R01 will directly advance nhlbi's strategic vision by identifying modifiable environmental FAC- tors and molecular mechanisms that contribute to CVH decline. We anticipate our results will inform early-life interventions and therapeutic strategies to preserve CVH and reduce lifelong CVD risk, particularly in vulnera- BLE pediatric populations.
Quick answers
Who received award R01HL183379?
R01HL183379 was awarded to Harvard Pilgrim Health Care, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2026.
How much is award R01HL183379 worth?
$571,839 has been obligated on R01HL183379.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award